Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- KNSA
- Price
- 45.38
- Stock movement up
- +0.01 (0.02%)
- Company name
- Kiniksa Pharmaceuticals Ltd
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 2.05B
- Ent value
- 2.05B
- Price/Sales
- 3.43
- Price/Book
- 3.83
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 57.06
- Forward P/E
- 29.76
- PEG
- -
- EPS growth
- -27.38%
- 1 year return (CAGR)
- 130.94%
- 3 year return (CAGR)
- 48.49%
- 5 year return (CAGR)
- 15.12%
- 10 year return (CAGR)
- -
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
KNSA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 57.06 |
| Price to OCF | 19.92 |
| Price to FCF | 20.14 |
| Price to EBITDA | 45.44 |
| EV to EBITDA | 45.49 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.43 |
| Price to Book | 3.83 |
| EV to Sales | 3.43 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 45.16M |
| EPS (TTM) | 0.46 |
| FCF per share (TTM) | 1.30 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 597.97M |
| Gross profit (TTM) | 315.52M |
| Operating income (TTM) | 38.15M |
| Net income (TTM) | 35.92M |
| EPS (TTM) | 0.46 |
| EPS (1y forward) | 1.52 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 52.76% |
| Operating margin (TTM) | 6.38% |
| Profit margin (TTM) | 6.01% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 174.86M |
| Net receivables | 51.74M |
| Total current assets | 475.53M |
| Goodwill | 0.00 |
| Intangible assets | 15.50M |
| Property, plant and equipment | 19.55M |
| Total assets | 712.33M |
| Accounts payable | 6.15M |
| Short/Current long term debt | 9.72M |
| Total current liabilities | 123.59M |
| Total liabilities | 176.95M |
| Shareholder's equity | 535.38M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 102.86M |
| Capital expenditures (TTM) | 1.13M |
| Free cash flow (TTM) | 101.73M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 6.71% |
| Return on Assets | 5.04% |
| Return on Invested Capital | 6.68% |
| Cash Return on Invested Capital | 18.91% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 44.97 |
| Daily high | 45.58 |
| Daily low | 43.55 |
| Daily Volume | 552K |
| All-time high | 45.38 |
| 1y analyst estimate | 55.00 |
| Beta | 0.05 |
| EPS (TTM) | 0.46 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 3 Mar 2026 |
Downside potential
Loading...
Downside potential data
| KNSA | S&P500 | |
| Current price drop from All-time high | -4.16% | -0.70% |
| Highest price drop | -83.06% | -56.47% |
| Date of highest drop | 18 Oct 2019 | 9 Mar 2009 |
| Avg drop from high | -41.55% | -10.84% |
| Avg time to new high | 43 days | 12 days |
| Max time to new high | 1724 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
2.05B
Marketcap category
Mid-cap
Description
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.
Employees
315
Website
Investor relations
-
SEC filings
CEO
Sanj K. Patel
Country
USA
City
Hamilton HM
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page